Piper Sandler has initiated its coverage of RxSight (RXST, Financial) with a Neutral rating, setting a price target of $18. The firm has expressed interest in RxSight's innovative light adjustable lens technology, which positions the company within the expansive and evolving intraocular lens market.
Despite the promising technology, Piper Sandler remains cautious. The investment firm is adopting a "wait-and-see" stance due to limited current visibility into RxSight's business operations, emerging competitive pressures, and concerns about a potentially challenging macroeconomic climate. These elements contribute to their neutral outlook, balancing interest in the company's unique offerings with the broader market conditions and competitive landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for RxSight Inc (RXST, Financial) is $25.89 with a high estimate of $42.00 and a low estimate of $16.00. The average target implies an upside of 79.53% from the current price of $14.42. More detailed estimate data can be found on the RxSight Inc (RXST) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, RxSight Inc's (RXST, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for RxSight Inc (RXST, Financial) in one year is $58.81, suggesting a upside of 307.84% from the current price of $14.42. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the RxSight Inc (RXST) Summary page.
